Published in Antimicrob Agents Chemother on January 19, 2010
New β-lactamase inhibitors: a therapeutic renaissance in an MDR world. Antimicrob Agents Chemother (2013) 1.47
Design, synthesis, and crystal structures of 6-alkylidene-2'-substituted penicillanic acid sulfones as potent inhibitors of Acinetobacter baumannii OXA-24 carbapenemase. J Am Chem Soc (2010) 1.12
The intrinsic resistome of bacterial pathogens. Front Microbiol (2013) 1.05
Novel β-lactamase inhibitors: a therapeutic hope against the scourge of multidrug resistance. Front Microbiol (2013) 0.99
Structural origins of oxacillinase specificity in class D β-lactamases. Antimicrob Agents Chemother (2013) 0.97
Class D β-lactamases: a reappraisal after five decades. Acc Chem Res (2013) 0.92
Activities of ceftazidime, ceftaroline, and aztreonam alone and combined with avibactam against isogenic Escherichia coli strains expressing selected single β-lactamases. Diagn Microbiol Infect Dis (2015) 0.84
One ring to rule them all: Current trends in combating bacterial resistance to the β-lactams. Protein Sci (2016) 0.82
LN-1-255, a penicillanic acid sulfone able to inhibit the class D carbapenemase OXA-48. J Antimicrob Chemother (2016) 0.76
Effect of the β-Lactamase Inhibitor Vaborbactam Combined with Meropenem against Serine Carbapenemase-Producing Enterobacteriaceae. Antimicrob Agents Chemother (2016) 0.75
Activity of the β-Lactamase inhibitor LN-1-255 against carbapenem-hydrolyzing class D β-lactamases from Acinetobacter baumannii. Antimicrob Agents Chemother (2017) 0.75
Overcoming an Extremely Drug Resistant (XDR) Pathogen: Avibactam Restores Susceptibility to Ceftazidime for Burkholderia cepacia Complex Isolates from Cystic Fibrosis Patients. ACS Infect Dis (2017) 0.75
Studies on lysogenesis. I. The mode of phage liberation by lysogenic Escherichia coli. J Bacteriol (1951) 28.27
A functional classification scheme for beta-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother (1995) 26.51
Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev (2001) 15.81
Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae. Antimicrob Agents Chemother (2004) 7.96
Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother (2007) 7.84
Updated functional classification of beta-lactamases. Antimicrob Agents Chemother (2009) 7.16
Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin Microbiol Infect (2006) 6.40
Bacterial resistance to beta-lactam antibiotics: compelling opportunism, compelling opportunity. Chem Rev (2005) 4.48
Diversity, epidemiology, and genetics of class D beta-lactamases. Antimicrob Agents Chemother (2009) 4.33
New beta-lactamases in gram-negative bacteria: diversity and impact on the selection of antimicrobial therapy. Clin Infect Dis (2001) 4.17
Characterization of OXA-25, OXA-26, and OXA-27, molecular class D beta-lactamases associated with carbapenem resistance in clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother (2001) 4.15
Lysogeny at mid-twentieth century: P1, P2, and other experimental systems. J Bacteriol (2004) 4.11
OXA-24, a novel class D beta-lactamase with carbapenemase activity in an Acinetobacter baumannii clinical strain. Antimicrob Agents Chemother (2000) 4.08
Kinetic interactions of tazobactam with beta-lactamases from all major structural classes. Antimicrob Agents Chemother (1993) 3.74
Contribution of acquired carbapenem-hydrolyzing oxacillinases to carbapenem resistance in Acinetobacter baumannii. Antimicrob Agents Chemother (2005) 3.41
Kinship and diversification of bacterial penicillin-binding proteins and beta-lactamases. Antimicrob Agents Chemother (1998) 3.37
Genetic and functional analysis of the chromosome-encoded carbapenem-hydrolyzing oxacillinase OXA-40 of Acinetobacter baumannii. Antimicrob Agents Chemother (2003) 3.19
OXA-type carbapenemases. J Antimicrob Chemother (2006) 3.15
Acquired carbapenem-hydrolyzing beta-lactamases and their genetic support. Curr Pharm Biotechnol (2002) 3.11
OXA-28, an extended-spectrum variant of OXA-10 beta-lactamase from Pseudomonas aeruginosa and its plasmid- and integron-located gene. Antimicrob Agents Chemother (2001) 3.00
OXA-14, another extended-spectrum variant of OXA-10 (PSE-2) beta-lactamase from Pseudomonas aeruginosa. Antimicrob Agents Chemother (1995) 2.77
OXA-type beta-lactamases. Curr Pharm Des (1999) 2.76
A comparative study of class-D beta-lactamases. Biochem J (1993) 2.68
OXA (beta)-lactamases in Acinetobacter: the story so far. J Antimicrob Chemother (2005) 2.32
Critical involvement of a carbamylated lysine in catalytic function of class D beta-lactamases. Proc Natl Acad Sci U S A (2001) 2.21
Chemical studies on the inactivation of Escherichia coli RTEM beta-lactamase by clavulanic acid. Biochemistry (1978) 2.12
Multicity outbreak of carbapenem-resistant Acinetobacter baumannii isolates producing the carbapenemase OXA-40. Antimicrob Agents Chemother (2006) 1.94
Crystal structure of the OXA-48 beta-lactamase reveals mechanistic diversity among class D carbapenemases. Chem Biol (2009) 1.93
Mutagenesis of amino acid residues in the SHV-1 beta-lactamase: the premier role of Gly238Ser in penicillin and cephalosporin resistance. Biochim Biophys Acta (2001) 1.92
Insights into class D beta-lactamases are revealed by the crystal structure of the OXA10 enzyme from Pseudomonas aeruginosa. Structure (2000) 1.84
Crystal structure of the class D beta-lactamase OXA-10. Nat Struct Biol (2000) 1.72
Comparison of beta-lactamases of classes A and D: 1.5-A crystallographic structure of the class D OXA-1 oxacillinase. Protein Sci (2003) 1.67
Biochemical characterization of the naturally occurring oxacillinase OXA-50 of Pseudomonas aeruginosa. Antimicrob Agents Chemother (2004) 1.66
Crystal structure of the carbapenemase OXA-24 reveals insights into the mechanism of carbapenem hydrolysis. Proc Natl Acad Sci U S A (2007) 1.63
Probing active site chemistry in SHV beta-lactamase variants at Ambler position 244. Understanding unique properties of inhibitor resistance. J Biol Chem (2006) 1.60
OXA-17, a further extended-spectrum variant of OXA-10 beta-lactamase, isolated from Pseudomonas aeruginosa. Antimicrob Agents Chemother (1999) 1.49
Inhibition of TEM-2 beta-lactamase from Escherichia coli by clavulanic acid: observation of intermediates by electrospray ionization mass spectrometry. Biochemistry (1996) 1.42
Beta-lactamases: a survey of protein diversity. Curr Drug Targets Infect Disord (2003) 1.41
Understanding resistance to beta-lactams and beta-lactamase inhibitors in the SHV beta-lactamase: lessons from the mutagenesis of SER-130. J Biol Chem (2003) 1.41
Clavulanic acid inactivation of SHV-1 and the inhibitor-resistant S130G SHV-1 beta-lactamase. Insights into the mechanism of inhibition. J Biol Chem (2005) 1.37
Rational design of a beta-lactamase inhibitor achieved via stabilization of the trans-enamine intermediate: 1.28 A crystal structure of wt SHV-1 complex with a penam sulfone. J Am Chem Soc (2006) 1.36
High-resolution X-ray structure of an acyl-enzyme species for the class D OXA-10 beta-lactamase. J Am Chem Soc (2002) 1.36
The discovery and development of modified penicillin- and cephalosporin-derived beta-lactamase inhibitors. Curr Med Chem (2004) 1.09
Decreased susceptibility to cefepime in a clinical strain of Escherichia coli related to plasmid- and integron-encoded OXA-30 beta-lactamase. Antimicrob Agents Chemother (2003) 1.08
Evaluation of penicillin-based inhibitors of the class A and B beta-lactamases from Bacillus anthracis. Biochem Biophys Res Commun (2004) 1.08
Strategic design of an effective beta-lactamase inhibitor: LN-1-255, a 6-alkylidene-2'-substituted penicillin sulfone. J Biol Chem (2008) 1.07
Inhibition of OXA-1 beta-lactamase by penems. Antimicrob Agents Chemother (2008) 1.04
OXA-46, a new class D beta-lactamase of narrow substrate specificity encoded by a blaVIM-1-containing integron from a Pseudomonas aeruginosa clinical isolate. Antimicrob Agents Chemother (2005) 1.04
Inactivation of CMY-2 beta-lactamase by tazobactam: initial mass spectroscopic characterization. Biochim Biophys Acta (2001) 1.02
Evidence of dimerisation among class D beta-lactamases: kinetics of OXA-14 beta-lactamase. Biochim Biophys Acta (2001) 0.95
The synthesis and evaluation of 6-alkylidene-2'beta-substituted penam sulfones as beta-lactamase inhibitors. Bioorg Med Chem Lett (1999) 0.93
Cephalosporin-derived inhibitors of beta-lactamase. Part 4: The C3 substituent. Bioorg Med Chem Lett (2002) 0.91
Distribution of beta-lactamases in Acinetobacter baumannii clinical isolates and the effect of Syn 2190 (AmpC inhibitor) on the MICs of different beta-lactam antibiotics. J Antimicrob Chemother (2002) 0.91
Inhibition of class D beta-lactamases by diaroyl phosphates. Biochemistry (2005) 0.88
Inhibition of class D beta-lactamases by acyl phosphates and phosphonates. Antimicrob Agents Chemother (2005) 0.84
Role of E166 in the imine to enamine tautomerization of the clinical beta-lactamase inhibitor sulbactam. Biochemistry (2009) 0.82
The synthesis and evaluation of 3-substituted-7-(alkylidene)cephalosporin sulfones as beta-lactamase inhibitors. Bioorg Med Chem Lett (2000) 0.81
Synthesis and evaluation of ketophosph(on)ates as beta-lactamase inhibitors. J Org Chem (2006) 0.78
Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev (2005) 15.72
Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother (2007) 7.84
Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis (2013) 6.60
Three decades of beta-lactamase inhibitors. Clin Microbiol Rev (2010) 5.54
Analysis of antibiotic resistance genes in multidrug-resistant Acinetobacter sp. isolates from military and civilian patients treated at the Walter Reed Army Medical Center. Antimicrob Agents Chemother (2006) 4.80
International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial Infections. Ann Intern Med (2004) 4.75
Comparative genome sequence analysis of multidrug-resistant Acinetobacter baumannii. J Bacteriol (2008) 4.42
Better tests, better care: improved diagnostics for infectious diseases. Clin Infect Dis (2013) 4.27
10 x '20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis (2013) 4.07
Extended-spectrum beta-lactamases in Klebsiella pneumoniae bloodstream isolates from seven countries: dominance and widespread prevalence of SHV- and CTX-M-type beta-lactamases. Antimicrob Agents Chemother (2003) 3.92
Characterization of blaKPC-containing Klebsiella pneumoniae isolates detected in different institutions in the Eastern USA. J Antimicrob Chemother (2009) 3.82
Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis (2004) 3.75
Sporadic and familial CJD: classification and characterisation. Br Med Bull (2003) 3.66
Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system. Antimicrob Agents Chemother (2009) 2.96
"Stormy waters ahead": global emergence of carbapenemases. Front Microbiol (2013) 2.74
Carbapenems: past, present, and future. Antimicrob Agents Chemother (2011) 2.61
Molecular dissection of the evolution of carbapenem-resistant multilocus sequence type 258 Klebsiella pneumoniae. Proc Natl Acad Sci U S A (2014) 2.56
Chronic wasting disease of elk: transmissibility to humans examined by transgenic mouse models. J Neurosci (2005) 2.46
Emergence of blaKPC-containing Klebsiella pneumoniae in a long-term acute care hospital: a new challenge to our healthcare system. J Antimicrob Chemother (2009) 2.28
The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity. Exp Cell Res (2007) 2.27
Multiplex real-time PCR assay for detection and classification of Klebsiella pneumoniae carbapenemase gene (bla KPC) variants. J Clin Microbiol (2010) 2.18
Increasing prevalence and dissemination of NDM-1 metallo-β-lactamase in India: data from the SMART study (2009). J Antimicrob Chemother (2011) 2.18
Occurrence, distribution, and origins of Streptococcus pneumoniae Serotype 6C, a recently recognized serotype. J Clin Microbiol (2008) 2.17
Inhibition of LpxC protects mice from resistant Acinetobacter baumannii by modulating inflammation and enhancing phagocytosis. MBio (2012) 2.15
In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin. Antimicrob Agents Chemother (2009) 2.12
The continuing challenge of ESBLs. Curr Opin Pharmacol (2007) 2.12
Isolation and characterization of an autoinducer synthase from Acinetobacter baumannii. J Bacteriol (2008) 2.02
Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes. Diagn Microbiol Infect Dis (2013) 2.01
Inhibitor resistance in the KPC-2 beta-lactamase, a preeminent property of this class A beta-lactamase. Antimicrob Agents Chemother (2009) 1.96
Carbapenem-resistant Acinetobacter baumannii and Klebsiella pneumoniae across a hospital system: impact of post-acute care facilities on dissemination. J Antimicrob Chemother (2010) 1.94
Genetic factors associated with elevated carbapenem resistance in KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother (2010) 1.94
Exploring the role of a conserved class A residue in the Ω-Loop of KPC-2 β-lactamase: a mechanism for ceftazidime hydrolysis. J Biol Chem (2012) 1.93
Metal binding and oxidation of amyloid-beta within isolated senile plaque cores: Raman microscopic evidence. Biochemistry (2003) 1.89
Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States. Antimicrob Agents Chemother (2008) 1.89
Identification of a new allelic variant of the Acinetobacter baumannii cephalosporinase, ADC-7 beta-lactamase: defining a unique family of class C enzymes. Antimicrob Agents Chemother (2005) 1.88
Outbreak of colistin-resistant, carbapenem-resistant Klebsiella pneumoniae in metropolitan Detroit, Michigan. Antimicrob Agents Chemother (2010) 1.87
In vitro activity of NXL104 in combination with beta-lactams against Klebsiella pneumoniae isolates producing KPC carbapenemases. Antimicrob Agents Chemother (2009) 1.80
The threat of antibiotic resistance in Gram-negative pathogenic bacteria: beta-lactams in peril! Curr Opin Microbiol (2005) 1.77
Development of a sensitive and specific enzyme-linked immunosorbent assay for detecting and quantifying CMY-2 and SHV beta-lactamases. J Clin Microbiol (2002) 1.75
3-nitropropionic acid is a suicide inhibitor of mitochondrial respiration that, upon oxidation by complex II, forms a covalent adduct with a catalytic base arginine in the active site of the enzyme. J Biol Chem (2005) 1.75
Crystal structure of KPC-2: insights into carbapenemase activity in class A beta-lactamases. Biochemistry (2007) 1.74
Complete nucleotide sequences of blaKPC-4- and blaKPC-5-harboring IncN and IncX plasmids from Klebsiella pneumoniae strains isolated in New Jersey. Antimicrob Agents Chemother (2012) 1.70
Outcomes and genetic relatedness of carbapenem-resistant enterobacteriaceae at Detroit medical center. Infect Control Hosp Epidemiol (2011) 1.70
Ultrahigh resolution structure of a class A beta-lactamase: on the mechanism and specificity of the extended-spectrum SHV-2 enzyme. J Mol Biol (2003) 1.66
Treatment and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream infections. Diagn Microbiol Infect Dis (2011) 1.64
Identification of novel proteinase K-resistant C-terminal fragments of PrP in Creutzfeldt-Jakob disease. J Biol Chem (2003) 1.61
Probing active site chemistry in SHV beta-lactamase variants at Ambler position 244. Understanding unique properties of inhibitor resistance. J Biol Chem (2006) 1.60
Complete nucleotide sequence of a blaKPC-harboring IncI2 plasmid and its dissemination in New Jersey and New York hospitals. Antimicrob Agents Chemother (2013) 1.59
Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother (2010) 1.58
LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1. Hum Mol Genet (2012) 1.56
Evaluation of a commercial microarray system for detection of SHV-, TEM-, CTX-M-, and KPC-type beta-lactamase genes in Gram-negative isolates. J Clin Microbiol (2010) 1.55
Genomewide analysis of divergence of antibiotic resistance determinants in closely related isolates of Acinetobacter baumannii. Antimicrob Agents Chemother (2010) 1.55
Use of denaturing gradient gel electrophoresis for analysis of the stool microbiota of hospitalized patients. J Microbiol Methods (2003) 1.54
The Roc domain of leucine-rich repeat kinase 2 is sufficient for interaction with microtubules. J Neurosci Res (2008) 1.54
First clinical cases of OXA-48-producing carbapenem-resistant Klebsiella pneumoniae in the United States: the "menace" arrives in the new world. J Clin Microbiol (2012) 1.52
Infections with nontyphoidal Salmonella species producing TEM-63 or a novel TEM enzyme, TEM-131, in South Africa. Antimicrob Agents Chemother (2004) 1.52
New insights into dissemination and variation of the health care-associated pathogen Acinetobacter baumannii from genomic analysis. MBio (2014) 1.51
The KQ element, a complex genetic region conferring transferable resistance to carbapenems, aminoglycosides, and fluoroquinolones in Klebsiella pneumoniae. Antimicrob Agents Chemother (2008) 1.47
New β-lactamase inhibitors: a therapeutic renaissance in an MDR world. Antimicrob Agents Chemother (2013) 1.47
Multiplex real-time PCR for detection of an epidemic KPC-producing Klebsiella pneumoniae ST258 clone. Antimicrob Agents Chemother (2012) 1.46
"Salvage microbiology": detection of bacteria directly from clinical specimens following initiation of antimicrobial treatment. PLoS One (2013) 1.45
Genetic analysis of surface motility in Acinetobacter baumannii. Microbiology (2011) 1.44
Malaria parasite invasion of the mosquito salivary gland requires interaction between the Plasmodium TRAP and the Anopheles saglin proteins. PLoS Pathog (2009) 1.44
Extended-spectrum beta-lactamases in multidrug-resistant Escherichia coli: changing the therapy for hospital-acquired and community-acquired infections. Clin Infect Dis (2006) 1.43
Antibody to DNA detects scrapie but not normal prion protein. Proc Natl Acad Sci U S A (2004) 1.43
New Delhi metallo-β-lactamase and multidrug resistance: a global SOS? Clin Infect Dis (2011) 1.41
Beta-lactamases: a survey of protein diversity. Curr Drug Targets Infect Disord (2003) 1.41
Understanding resistance to beta-lactams and beta-lactamase inhibitors in the SHV beta-lactamase: lessons from the mutagenesis of SER-130. J Biol Chem (2003) 1.41
Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase. Antimicrob Agents Chemother (2010) 1.41
What's new in antibiotic resistance? Focus on beta-lactamases. Drug Resist Updat (2006) 1.41